GLP-1 Tirzepatide ReviewIndependent · S.J Partners LLC
Prices 6 verified of 54 Rubric v1.0-draft Prices verified 0 of 54 Evidence records 32 verified Corrections open log

Journal

Cheapest FDA-Approved vs Compounded GLP-1 Options

Separate starter, ongoing, annual and dose-tier prices

Direct answer

The cheapest FDA-approved GLP-1 for weight loss is now $149 a month — orforglipron through LillyDirect or oral Wegovy tablets through NovoCare. Most compounded programmes run $169 to $399. A compounded programme priced above $299 costs more than brand Zepbound direct from the manufacturer, and several of them are.

Answer last reviewed: 2026-07-24

The comparison everyone stopped updating

For two years the arithmetic was simple. Brand GLP-1s listed above $1,000 a month, compounded alternatives ran $200 to $400, and the gap was the entire business model of GLP-1 telehealth.

Brand prices then fell sharply, and most comparison pages never updated. Zepbound is now $299 to $449 direct from LillyDirect. Wegovy is $349 through NovoCare, with oral Wegovy tablets at $149. Orforglipron, Lilly's approved oral GLP-1, starts at $149. With commercial insurance that covers them, either brand can land near $25.

Against a compounded market that mostly prices between $169 and $399, that is no longer a large gap. In parts of the market it has inverted.

Where the inversion actually bites

Sixteen of the compounded offerings in our pricing dataset cost more than $299 a month. Every one of those is more expensive than brand Zepbound bought directly from its manufacturer — an FDA-approved product, reviewed for safety, effectiveness and manufacturing quality, supplied through the company that makes it.

Some of the differences are extreme. Several telehealth platforms resell brand-name drugs close to retail: one lists brand Wegovy at $1,794 a month all-in when NovoCare sells the identical medicine direct for $349. That is disclosed pricing rather than fraud, but it is a fourfold to twelvefold difference for the same product from the same manufacturer.

The catch, stated fairly

Two things complicate the picture, and a page that omitted them would be doing what we are criticising.

Titration. The $149 orforglipron price is the 0.8 mg starter dose. It rises to $199, then $299, then $349 as the dose increases — with its own 45-day refill rule that returns it to $299 if you refill in time. Zepbound behaves similarly: $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 to 15 mg, and the rate holds only with a refill inside 45 days. Some compounded programmes charge one flat price at every dose, which is worth real money to a patient at a maintenance dose.

The lowest compounded prices are genuinely lower. Microdose programmes reach $110 to $147 a month. But a microdose sits below every dose used in the trials, which is a different product with a smaller expected effect, not a discount on the same treatment.

How to work out which applies to you

Three questions settle it.

  1. What dose will I actually be on? If you expect to maintain at a low dose, the approved oral at $149 is hard to beat. If you expect a high maintenance dose, a flat-rate compounded programme may win on arithmetic.
  2. Does my insurance cover a brand product? Check before anything else. Coverage changes the answer completely and most people never ask.
  3. Am I comparing like with like? A compounded microdose against an approved full dose is not a price comparison, it is two different treatments with two different expected effects.

What this does not say

It does not say compounded medicines are bad, or that everyone should switch. It says the price argument that justified the compounded market has weakened substantially, and that anyone paying more than $299 a month for a compounded product should know they could buy the FDA-approved version for less.

Mean weight reduction by drug and dose, from the trials that produced each figureSeparate trials, different durations and populations
Tirzepatide 15 mg (SURMOUNT-1)21%Oral semaglutide 25 mg, adherent (17%Injectable semaglutide 2.4 mg (SUR14%Oral semaglutide 25 mg, treatment-14%Orforglipron 17.2 mg (ATTAIN-1)12%Liraglutide (SCALE)8%
Show this figure as a table
ItemMean reductionEvidence
Tirzepatide 15 mg (SURMOUNT-1)21%Verified
Oral semaglutide 25 mg, adherent (OASIS 4)17%Verified
Injectable semaglutide 2.4 mg (SURMOUNT-5)14%Verified
Oral semaglutide 25 mg, treatment-policy (OASIS 4)14%Verified
Orforglipron 17.2 mg (ATTAIN-1)12%Provider-reported
Liraglutide (SCALE)8%Provider-reported
These come from different trials and are not a head-to-head comparison. Durations differ (64 to 72 weeks) and estimands differ. Only SURMOUNT-5 compared two of these drugs directly.
Price against efficacy, for the FDA-approved options
ProductStarting self-pay priceReported mean reductionTrial
Zepbound (tirzepatide) injectable$299/mo directabout 20.9% at 15 mgSURMOUNT-1, 72 weeks
Wegovy pill (oral semaglutide 25 mg)$149/mo starting dose13.6–16.6% depending on estimandOASIS 4, 64 weeks
Wegovy injectable (semaglutide 2.4 mg)$349/mo maintenanceabout 13.7%SURMOUNT-5, 72 weeks
Foundayo (orforglipron)$149/mo starting doseabout 11–12.4% at 17.2 mgATTAIN-1, 72 weeks
Both $149 products are the least effective approved options in this table. That does not make them bad choices — it makes a price comparison that omits efficacy an incomplete one.
Monthly cost, approved against compounded
FDA-approved oral, starterOrforglipron $149Oral Wegovy $149FDA-approved injectable, direcZepbound 2.5mg $299Wegovy maintenance $349Cheapest compounded standardTirzepatide $169Semaglutide $133Typical compounded standardTirzepatide $280Semaglutide $199OrforglipronOral Wegovy
Show this figure as a table
ItemOrforglipronOral Wegovy
FDA-approved oral, starter$149$149
FDA-approved injectable, direct$299$349
Cheapest compounded standard$169$133
Typical compounded standard$280$199
Competitor figures third-party reported, captured 6 July 2026. Manufacturer pricing from Lilly's and Novo's own self-pay pages.
Where the approved price goes as the dose rises
Orforglipron 0.8 mg$149Orforglipron 2.5 mg$199Orforglipron 5.5–9 mg$299Orforglipron 14.5–17.2 mg$349
Show this figure as a table
ItemValueEvidence
Orforglipron 0.8 mg$149Verified
Orforglipron 2.5 mg$199Verified
Orforglipron 5.5–9 mg$299Verified
Orforglipron 14.5–17.2 mg$349Verified
Drops back to $299 on refill within 45 days of the previous delivery.
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Questions readers actually ask

What is the cheapest FDA-approved GLP-1 for weight loss?

At the starting dose, $149 a month — orforglipron through LillyDirect, or oral Wegovy tablets through NovoCare. Both rise with dose.

Is compounded always cheaper than brand?

No. Not any more. Sixteen compounded offerings in our dataset cost more than brand Zepbound bought direct from Lilly at $299.

Why do some telehealth platforms charge over $1,000 for brand drugs?

They resell at close to retail rather than routing you to the manufacturer's own self-pay programme. Always price a brand drug at LillyDirect or NovoCare before buying it through a platform.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Cheapest FDA-Approved vs Compounded GLP-1 Options.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/cheapest-fda-approved-vs-compounded-glp1/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Report an error
Comparing 0 of 4